Bispecifics in MM: Future Directions in Care
Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.
Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma
Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.
Bispecifics in MM: mSMART Guidelines for Monitoring and Managing AEs
Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.
Insights from Experts at Mayo Clinic: Step-up and Treatment Dosing of Bispecifics
A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.
Insights from Experts at Mayo Clinic: Sequencing Therapies in MM
Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.
Other Bispecifics in Development for Multiple Myeloma
Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.
MonumenTAL-1: Data Updates of Non-BCMA Bispecifics in MM
Shared insight from Rafael Fonseca, MD, on data from MonumenTAL-1 and the use of talquetamab therapy in patients with relapsed/refractory multiple myeloma.
MagnetisMM-1: Data Updates of Anti-BCMA Bispecifics in MM
Expert perspectives from Joselle Cook, MBBS, on use of elranatamab in relapsed/refractory multiple myeloma based on data from the MagnetisMM-1 trial.
MajesTEC-1: Data Updates of Anti-BCMA Bispecifics in MM
Expert Shaji Kumar, MD, spearheads a review of data from MajesTEC-1 and use of teclistamab therapy in patients with relapsed/refractory multiple myeloma.
Overview of Treatment Options in Relapsed/Refractory Multiple Myeloma
Opening the panel’s discussion on multiple myeloma management, Rafael Fonseca, MD, reviews treatment options available to patients at early or late relapse.
IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.
Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.
Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.
Comparing Quadruplet Combination Treatment Regimens in NDMM
The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.
Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.
Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
The panel reviews possible treatment approaches for patients with high-risk NDMM, and how MRD negativity affects their decision making.
Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
Sandy Wong, MD, presents data from a subgroup analysis of the GRIFFIN and MASTER trials in patients with transplant-eligible NDMM.
Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
Drs Lesokhin and Wong detail their strategies for maintenance therapy after transplant in NDMM treatment.
Treatment Approaches in Transplant-Eligible NDMM
Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.
GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
Shaji Kumar, MD, presents updated data from the GRIFFIN trial investigating combination daratumumab, lenalidomide, bortezomib, and dexamethasone for the treatment of transplant-eligible newly-diagnosed multiple myeloma (NDMM).
Bispecifics and CAR-T Therapies in the Management of Multiple Myeloma
Broad discussion on novel therapies, including bispecifics and CAR-T therapies, that are evolving the treatment landscape of multiple myeloma.
Selecting and Sequencing Therapy in Relapsed/Refractory MM
Panelists take a broad look at treatment selection and sequencing through multiple lines of therapy in patients with multiple myeloma.
Case Presentation 3: Managing NDMM in Frail Patients
Moving to the last patient case of newly diagnosed multiple myeloma, expert panelists work together to define patient frailty in this setting and discuss how frail patients are treated in practice.
Considerations for Incorporating Daratumumab-Containing Regimens in NDMM
Shared insight on optimizing selection and use of daratumumab-containing regimens in NDMM, with regard for clinical trial readouts in this setting.
Case Presentation 2: Transplant-Ineligible NDMM and Treatment With the DRd Regimen
Experts review a second patient case wherein transplant-ineligible newly diagnosed multiple myeloma was treated with the daratumumab, lenalidomide and dexamethasone regimen and how updated data from the MAIA trial can be incorporated into clinical practice.
Role for Transplantation and Maintenance Therapy in NDMM
Considerations for assessing eligibility of patients for transplantation for NDMM and how maintenance therapy may be initiated in the post-transplant setting.
Case Presentation 1: Selecting Therapy in Transplant-Ineligible NDMM
Centering discussion on a patient case of transplant-ineligible newly diagnosed multiple myeloma, experts consider how they would approach workup and management.
NDMM Management: Assessing Response and Determining Duration of Therapy
Comprehensive insight on optimizing newly diagnosed multiple myeloma management, ranging from response assessment to use of consolidation and maintenance therapy.
Frontline Quadruplet Therapy in NDMM: GMMG-HD7
Shared insight on the GMMG-HD7 study, which utilized a frontline isatuximab-containing quadruplet regimen in patients with newly diagnosed multiple myeloma.
Frontline Quadruplet Therapy in NDMM: GRIFFIN and MASTER Studies
Expert perspectives on frontline daratumumab-containing quadruplet regimens in the context of recent clinical trials in newly diagnosed multiple myeloma.
2 Clarke Drive Cranbury, NJ 08512